Trial · NCT02737501
Results by group29
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 29
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Randomized Phase: Brigatinib 90 mg QD/180 QD | 24.016 | 95% Confidence Interval 18.46 to 43.20 | months | |
| Progression-free Survival (PFS) | Randomized Phase: Crizotinib 250 mg BID | 11.072 | 95% Confidence Interval 9.13 to 13.01 | months | |
| Progression-free Survival (PFS) | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 16.821 | 95% Confidence Interval 10.12 to 23.85 | months | |
| Confirmed Objective Response Rate (ORR) | Randomized Phase: Brigatinib 90 mg QD/180 QD | 74.5 | 95% Confidence Interval 66.30 to 81.52 | percentage of participants | |
| Confirmed Objective Response Rate (ORR) | Randomized Phase: Crizotinib 250 mg BID | 62.3 | 95% Confidence Interval 53.68 to 70.42 | percentage of participants | |
| Confirmed Objective Response Rate (ORR) | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 56.9 | 95% Confidence Interval 44.04 to 69.15 | percentage of participants | |
| Confirmed Intracranial ORR (iORR) | Randomized Phase: Brigatinib 90 mg QD/180 QD | 66.0 | 95% Confidence Interval 50.69 to 79.14 | percentage of participants | |
| Confirmed Intracranial ORR (iORR) | Randomized Phase: Crizotinib 250 mg BID | 14.3 | 95% Confidence Interval 5.94 to 27.24 | percentage of participants | |
| Confirmed Intracranial ORR (iORR) | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 35.7 | 95% Confidence Interval 21.55 to 51.97 | percentage of participants | |
| Intracranial Progression Free Survival | Randomized Phase: Brigatinib 90 mg QD/180 QD | 23.951 | 95% Confidence Interval 12.91 to 30.78 | months | |
| Intracranial Progression Free Survival | Randomized Phase: Crizotinib 250 mg BID | 5.520 | 95% Confidence Interval 3.71 to 7.52 | months | |
| Intracranial Progression Free Survival | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 24.542 | 95% Confidence Interval 12.58 to NA | months | |
| Overall Survival (OS) | Randomized Phase: Brigatinib 90 mg QD/180 QD | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival (OS) | Randomized Phase: Crizotinib 250 mg BID | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival (OS) | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 35.023 | 95% Confidence Interval 30.42 to NA | months | |
| Duration of Response (DOR) | Randomized Phase: Brigatinib 90 mg QD/180 QD | 33.150 | Full Range 1.84 to 50.60 | months | |
| Duration of Response (DOR) | Randomized Phase: Crizotinib 250 mg BID | 13.832 | Full Range 1.45 to 49.81 | months | |
| Duration of Response (DOR) | Crossover Phase: Brigatinib 90 mg QD/180 mg QD | 19.154 | Full Range 1.97 to 33.15 | months | |
| Time to Response (TTR) | Randomized Phase: Brigatinib 90 mg QD/180 QD | 1.840 | Full Range 1.02 to 29.47 | months | |
| Time to Response (TTR) | Randomized Phase: Crizotinib 250 mg BID | 1.873 | Full Range 0.79 to 7.43 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02737501/results